21st International Congress » Neuropharmacology

1:15pm-2:45pm

All-trans-retinoic Acid pretreatment exhibits neuroprotective effect against 6-hydroxydopamine-induced hemi-parkinsonian rats

A. Morad Ganjeh (Karaj, Islamic Republic of Iran)

1:15pm-2:45pm

Application of a Qualitative Model to Elucidate the Role of the Alpha-Synuclein System in Parkinson’s Disease.

C. Friedrich, W. Zago, S. Gardai, G. Tonn, M. Reed (Cupertino, CA, USA)

1:15pm-2:45pm

Basal Ganglia and Limbic Striatal Regions are Differentially Affected by Pramipexole: D3 receptor – Mediated Changes in Markers of Synaptic Strength

M. Bailey, A. Persons, T.C. Napier (Chicago, IL, USA)

1:15pm-2:45pm

Curcumin I prevents the developmental defective sensorimotor patterns resulted from Lead poisoning in rat

H. BENAMMI, O. EL HIBA, H. GAMRANI (Marrakech, Morocco)

1:15pm-2:45pm

Curcumin I protect against copper induced neurobehavioral features of Parkinson’s disease in rat

A. Abbaoui, O. EL Hiba, H. Gamrani (Marrakech, Morocco)

1:15pm-2:45pm

Dextrometorphan/quinidine in Atypical Parkinsonisms and Huntington Disease

J. Etcheverry, M. Cesarini, G. Rojas, E. Gatto (Buenos Aires, Argentina)

1:15pm-2:45pm

Does levodopa-carbidopa intestinal gel in Parkinson’s disease patients increase the risk on polyneuropathy?

H. Moes, M. Drent, T. Laar (Groningen, Netherlands)

1:15pm-2:45pm

Identification of a trehalose treatment regimen with potential to be translated into a therapeutic for the treatment of Parkinson’s disease

J. Koprich, P. Howson, T. Johnston, M. Hill, P. Ravenscroft, J. Brotchie (Toronto, ON, Canada)

1:15pm-2:45pm

Is there a significant relationship between weight loss and prevalence of side effects of Parkinsonian medication? A retrospective, single-centre analysis, South Wales, UK.

B. Schroeder, E. Thomas, T. Williams, S. Mahon, B. Mohamed (Cardiff, United Kingdom)

1:15pm-2:45pm

MANF protects dopamine neurons and locomotion defect from Neurotoxin/Human alpha-synuclein-induced progressive Parkinson’s disease models in C.elegans.

Z. Zhang (Shanghai, China)

1:15pm-2:45pm

Mechanisms of sub-anesthetic ketamine infusions to reduce L-DOPA-induced dyskinesia: effects on striatal mTOR signaling and beta band oscillations in striatum and motor cortex

M. Bartlett, A. Flores, T. Ye, H. Dollish, K. Doyle, S. Cowen, S. Sherman, T. Falk (Tucson, AZ, USA)

1:15pm-2:45pm

Neuroprotective effects of antidepressant mirtazapine against dopaminergic neurodegeneration in cultured cells and in parkinsonian mice possibly by targeting astrocytes

M. Asanuma, I. Miyazaki, R. Kikuoka, S. Murakami, N. Isooka, Y. Kitamura (Okayama, Japan)

1:15pm-2:45pm

Neuroticism and depression is associated with impulse control disorder in Parkinson’s disease: a controlled study

N. Titova, N. Sotnikova, E. Katunina (Moscow, Russian Federation)

1:15pm-2:45pm

Onabotulinumtoxin A (Botox) displays superior activity to incobotulinumtoxinA (Xeomin) in multiple in vitro and in vivo assays

D. Canty, L. Le, J. Wang, G. Nicholson, A. Brideau-Andersen, L. Steward, B. Jacky, R. Broide, M. Washburn, D. Rupp (Irvine, CA, USA)

1:15pm-2:45pm

Piper betle L. Attenuates 6-OHDA Induced Apoptosis in SH-SY5Y Cells and Neuronal Injury in Caenorhabditis elegans Parkinson’s Model

G. Shanmugam, A. Mohankumar, P. Sundararaj (Coimbatore, India)

1:15pm-2:45pm

Piperine potentiate the neuroprotective effect of quercetin against MPTP induced neurotoxicity in rats

S. Singh, P. Kumar (Moga, India)

1:15pm-2:45pm

Protective effect of Myristicin against neurodegeneration in a 6-hydroxydopamine induced model of Parkinson’s disease in rats

A. Morad Ganjeh (Karaj, Islamic Republic of Iran)

1:15pm-2:45pm

Role of Apocyanin in modulating glial cell functions and associated inflammatory response in Lipopolysaccharide induced Parkinson’s disease model.

N. Sharma, B. Nehru (Chandigarh, India)

1:15pm-2:45pm

Rotenone induces astrocyte-mediated non-cell autonomous dopaminergic neurotoxicity

I. Miyazaki, S. Murakami, R. Kikuoka, N. Isooka, Y. Kitamura, M. Asanuma (Okayama, Japan)

1:15pm-2:45pm

Serum vitamin B12 levels in patients with Parkinson’s disease and its association with peripheral neuropathy and cognition

R. Kandadai, N. Mathukumali, S.S. Meka, S. Tandra, A. Kohat, M. Kanikannan, R. Borgohain (Hyd, India)

1:15pm-2:45pm

Study of neuroprotective effects of Ginsenside Rg3 , the prototypal epigenetic Sirtuin-1 activator, in targeting microglia activation and neurotrophic factor (NF) neural plasticity in MPTP model of Parkinson’s disease (PD)

H. Raheb, J. Hou, S. Chiu (London, ON, Canada)

1:15pm-2:45pm

The clinically-available anti-depressant mirtazapine alleviates both psychosis and dyskinesia in the MPTP-lesioned marmoset

I. Frouni, S. Nuara, N. Veyres, C. Kwan, M.-J. Harraka, V. Nafade, L. Sid-Otmane, J. Gourdon, H. Adjia, P. Huot (Montreal, QC, Canada)

1:15pm-2:45pm

The efficacy of continuous apomorphine infusion in advanced PD patients with cognitive impairments

R. Borgemeester, T. van Laar (Groningen, Netherlands)

1:15pm-2:45pm

The highly-selective metabotropic glutamate receptor 2 positive allosteric modulator LY-487,379 alleviates psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset

L. Sid-Otmane, S. Nuara, A. Hamadjida, N. Veyres, C. Rouillard, M. Panisset, J. Gourdon, P. Huot (Montreal, QC, Canada)

1:15pm-2:45pm

The highly-selective mGluR2 positive allosteric modulator LY-487,379 alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease

C. Kwan, I. Frouni, V. Nafade, D. Gagnon, M.-J. Wallman, L. Sid-Otmane, M. Parent, A. Parent, C. Rouillard, H. Adjia, P. Huot (Montreal, QC, Canada)

1:15pm-2:45pm

Using cognitive computing to identify compounds with antidyskinetic potential for Parkinson’s disease

N. Visanji, A. Lacoste, S. Ezell, S. Spangler, E. Argentinis, J. Brotchie, A. Lang, T. Johnston (Toronto, ON, Canada)